Clinical outcomes of transcatheter aortic valve implantation in oncology versus non-oncology patients with severe aortic stenosis: A systematic review and meta-analysis

Yumeng Song; Tianqi Chang; Yiyu GU; Yinan XU; Mingyang Zhang; Yutong Wang; Tingbo Jiang

Return

Clinical outcomes of transcatheter aortic valve implantation in oncology versus non-oncology patients with severe aortic stenosis: A systematic review and meta-analysis

VernacularTitle:经导管主动脉瓣置入术对合并主动脉瓣重度狭窄的肿瘤与非肿瘤患者疗效比较的系统评价与 Meta 分析
Author: Yumeng SONG ¹ ; Tianqi CHANG ¹ ; Yiyu GU ¹ ; Yinan XU ¹ ; Mingyang ZHANG ¹ ; Yutong WANG ¹ ; Tingbo JIANG ²
Author Information

1. The First Clinical Medical College of Soochow University, Suzhou, 215006, Jiangsu, P. R. China
2. Department of Cardiovascular Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, P. R. China
Publication Type:Journal Article
Keywords: Severe aortic stenosis; oncology; transcatheter aortic valve implantation; systematic review/meta-analysis
From: Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2022;29(05):634-641
CountryChina
Language:Chinese
Abstract: Objective To compare the clinical outcomes of transcatheter aortic valve implantation (TAVI) in oncology and non-oncology patients with severe aortic stenosis (AS). Methods A computer-based search in PubMed, The Cochrane Library, EMbase, CBM, CNKI and Wanfang databases from their date of inception to December 2021 was performed, together with reference screening, to identify eligible clinical trials. Two investigators screened the articles, extracted data, and evaluated quality independently. RevMan 5.3 and Stata 12.0 softwares were used for meta-analysis. Results The selected 8 cohort studies contained 57 988 patients, including 12 335 cancer patients and 45 653 non-cancer patients. The results of meta-analysis showed that in patients with cancer, the 30-day mortality [OR=0.74, 95%CI (0.65, 0.84), I2=0%, P<0.000 01], stroke [OR=0.87, 95%CI (0.76, 0.99), I2=0%, P=0.04] and acute kidney injury [OR=0.81, 95%CI (0.76, 0.85), I2=49%, P<0.000 01] were lower than those in patients without cancer. The 1-year mortality [OR=1.46, 95%CI (1.15, 1.86), I2=62%, P=0.002] and late mortality [OR=1.51, 95%CI (1.24, 1.85), I2=61%, P<0.000 1] were higher in patients with cancer. Conclusion It is effective and safe in cancer patients with severe AS undergoing TAVI. However, compared with patients without cancer, it is still high in long-term mortality, and further study of the role of TAVI in cancer patients with AS is necessary.